Composition

Each 1 ml contains:
Olopatadine (as HCl) ................................ 1 mg
Inactive ingredients: Benzalkonium chloride, sodium chloride, sodium phosphate dibasic anhydrous, sodium hydroxide or hydrochloric acid, purified water.

Therapeutic Indications

Treatment of ocular signs and symptoms of seasonal allergic conjunctivitis.

Dosage and Administration

The dose is one drop of OLOHISTINE in the conjunctival sac of the affected eye(s) twice daily (8 hourly).
Treatment may be maintained for up to four months, if considered necessary.
To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas, or other surfaces with the dropper tip of the bottle. Keep the bottle tightly closed when not in use.
In case of concomitant therapy with other topical ocular medicines, an interval of five to ten minutes should be allowed between successive applications.
Use in elderly:
No dosage adjustment in elderly patients is necessary.
Paediatric patients:
OLOHISTINE may be used in paediatric patients (three years of age and older) at the same dose as in adults.
Use in hepatic and renal impairment:
Olopatadine in the form of eye drops has not been studied in patients with renal or hepatic disease. However, no dosage adjustment is expected to be necessary in hepatic or renal impairment.

Contraindications

Hypersensitivity to the active substance or to any of the excipients.

Warnings and Precautions

Olohistine is an antiallergic/antihistaminic agent and, although administered topically, is absorbed systemically. If signs of serious reactions or hypersensitivity occur, discontinue the use of OLOHISTINE.
Benzalkonium chloride, which is commonly used as a preservative in ophthalmic products, has been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy. Since OLOHISTINE contains benzalkonium chloride, close monitoring is required with frequent or prolonged use in dry eye patients, or in conditions where the cornea is compromised.
Benzalkonium chloride may cause eye irritation.
Contact lenses:
Patients should be instructed to wait 10-15 minutes after instillation of OLOHISTINE before inserting contact lenses. Olohistine should not be administered while wearing contact